Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal

Chandra Sekhar Kuruva, P. Hemachandra Reddy

    Research output: Contribution to journalReview articlepeer-review

    40 Scopus citations


    Multiple cellular changes have been identified as being involved in Alzheimer's disease (AD) pathogenesis, including mitochondrial damage, synaptic loss, amyloid beta (Aβ) production and/or accumulation, inflammatory responses, and phosphorylated tau formation and/or accumulation. Studies have established that Aβ-induced synaptic dysfunction is dependent on abnormal amyloid precursor protein (APP) processing caused by β- and γ-secretases, resulting in the generation of Aβ. The Aβ formed as a result of abnormal APP processing induces phosphorylated tau and activates glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Here, we review the latest research on the development of Aβ modulators for neuroprotection in AD. We also review the use of molecular inhibitors as therapeutic targets in AD.

    Original languageEnglish (US)
    Pages (from-to)223-233
    Number of pages11
    JournalDrug Discovery Today
    Issue number2
    StatePublished - Feb 1 2017

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery


    Dive into the research topics of 'Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal'. Together they form a unique fingerprint.

    Cite this